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The cationic proinflammatory cytokine Interleukin 26 (IL-26) shows antibacterial activity 
and inhibits the replication of cytomegalovirus and hepatitis C virus. This study evaluates 
the early microbicidal activities of IL-26 against major bacterial species including multi-
resistant variants and Candida albicans. Recombinant IL-26 was bacterially expressed 
and studied for its microbicidal effects in culture. We show that IL-26 has strong 90% 
bactericidal activities against Enterococcus faecalis, Enterococcus faecium, Staphylococcus 
aureus, and Acinetobacter baumannii. Similarly, IL-26 sensitivity was also detectable in 
vancomycin-resistant Enterococcus species, methicillin-resistant S. aureus, and 
carbapenem-resistant A. baumannii clinical isolates. Additionally, a significant, albeit weak 
fungicidal effect against Candida albicans was observed. Activities against Escherichia 
coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were not detectable. The 
proinflammatory cytokine and kinocidin IL-26 shows strong bactericidal activities against 
A. baumannii and, almost selectively, against Gram-positive bacteria.
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INTRODUCTION
The highly cationic proinflammatory cytokine Interleukin 26 (IL-26) is a member of the IL-10 
family of cytokines. IL-26 is produced by different cell types, such as activated T cells or 
inflammatory fibroblasts, and stimulates the production of other proinflammatory cytokines 
in various cell types (Knappe et  al., 2000; Fickenscher et  al., 2002; Hör et  al., 2004; Corvaisier 
et  al., 2012; Braum et  al., 2013; Che et  al., 2014, 2017; Larochette et  al., 2019). IL-26 uses a 
specific, heterodimeric cytokine receptor consisting of IL-20R1 and IL-10R2 on epithelial cells, 
whereas its action on other cell types is independent of this receptor (Hör et  al., 2004; Sheikh 
et  al., 2004; Corvaisier et  al., 2012). Accordingly, elevated IL-26 levels were found in inflamed 
tissues or plasma of patients with different inflammatory diseases (Dambacher et  al., 2009; 
Corvaisier et  al., 2012; Che et  al., 2014, 2017; Miot et  al., 2014; Meller et  al., 2015; Konradsen 
et  al., 2016; Fujii et  al., 2017; Heftdal et  al., 2017; Poli et  al., 2017; Caiazzo et  al., 2018; 
Larochette et  al., 2019; Scala et  al., 2019; Brilland et  al., 2021). Moreover, IL-26 inhibits 
cytomegalovirus and hepatitis C virus replication and promotes the replication of vesicular 
stomatitis virus (Braum et  al., 2013; Miot et  al., 2014). IL-26 is a highly cationic protein with 
amphipathic helices, which are typical for cationic cell-penetrating peptides (Knappe et  al., 
2000; Meller et  al., 2015). IL-26 shares structural similarity with antimicrobial peptides (AMP) 
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and bacteriostatic activities of IL-26 against both Gram-positive 
and Gram-negative bacteria have been demonstrated (Meller 
et  al., 2015; Agak et  al., 2018; Woetmann et  al., 2018; Scala 
et  al., 2019). Recombinant IL-26 has a molecular weight of 
19 kDa and the formation of dimers, oligomers, and multimers 
has been described. Since IL-26 combines cytokine functions 
with antimicrobial activities, it belongs to the group of kinocidins 
(Yount et  al., 2004; Yeaman et  al., 2007; Larochette et  al., 
2019). This project targets the rapid, microbicidal activities 
of IL-26.
MATERIALS AND METHODS
Production of Recombinant Protein
Induction of IL-26 protein synthesis was achieved in Escherichia 
coli strain XL1blue, which is capable of producing IL-26  in 
inclusion bodies, by adding 1 mM isopropyl β-D-1-
thiogalactopyranoside and cultivation for 6 h (Knappe et  al., 
2000; Hör et  al., 2004). First, the bacteria were disrupted 
mechanically in 6 M guanidinium chloride with 0.1 M NaH2PO4, 
0.01 M Tris, and 100 mM β-mercaptoethanol. Bacterial debris 
was removed by centrifugation for 30 min at 8,873 × g and by 
sterile filtration. Nickel-chelate affinity chromatography was 
used for protein purification under denaturing conditions (Ni 
Sepharose 6 Fast Flow, GE Healthcare Life Sciences, 
Buckinghamshire, UK). Particle-bound IL-26 was eluted under 
increasing imidazole concentrations (40 mM, 500 mM, and 
600 mM). Eluate fractions were tested for 19 kDa bands in 
Coomassie-stained protein gels. Renaturation of relevant eluate 
fractions was achieved by dialysis for 24 h twice, at 4°C (20 mM 
HEPES, 1 mM MgCl2, 20 mM KCl, 0.1 mM EDTA, 1% glycerol, 
1 mM oxidated glutathione, and 5 mM reduced glutathione, 
pH 8.0).
Testing IL-26 for Functionality
The physiological STAT3 phosphorylation activity of the newly 
produced IL-26 was tested with the human colon carcinoma 
cell line COLO-205. IL-26 (5 μg/ml) was added for 45 min at 
37°C. Cell lysates were separated on protein gels and Western 
blots were probed with anti-phospho-STAT3 and anti-STAT3 
antibodies (anti-phospho-Tyr705 STAT3, #9131, rabbit; anti-
STAT3, #9132, rabbit) and horseradish peroxidase-conjugated 
anti-rabbit IgG antibodies (#7074, goat, Cell Signaling Technology, 
Beverly, United  States) as secondary reagent. Signals were 
detected by chemiluminescence (Figure  1) using a charged-
coupled device camera (LAS-3000, Fujifilm, Tokio, Japan). If 
phospho-STAT3 bands were detectable, the respective IL-26 
fraction was considered biologically active.
Testing for Antimicrobial Activity
Bacteria and C. albicans were initially grown on Columbia 
sheep blood agar at 37°C overnight and then for 20 h at 37°C 
in 10 ml tryptic soy broth (TSB) medium with 10 mM NaCl. 
Then, 50 μl of the culture was added to 10 ml of TSB/10 mM 
NaCl medium and incubated for 3 h at 37°C for reaching the 
logarithmic phase of growth and the optical density at 600 nm 
was determined. We  diluted the culture with 10 mM NaCl to 
reach target concentrations of 105 CFU/ml. Next, 100 μl of the 
microbial suspension was added to 100 μl of different concentrated 
IL-26 solutions (100, 30, 10, 3, and 1 μg/ml) to achieve final 
IL-26 concentrations in the wells of 50, 15, 5, 1.5, and 0.5 μg/ml. 
We always ran negative controls with pure dialysis buffer instead 
of the IL-26 solution, as well as positive controls with bacteria 
that were previously shown to be  highly sensitive to IL-26, 
when species with low or lacking IL-26 sensitivity were examined.
Immediately after the start of the treatment, and after 1, 
2, 3, and 4 h, 20 μl from each culture was sampled and diluted 
in a 0.85% NaCl solution and 100 μl of that dilution was 
pipetted on two lysogeny broth (LB) agar plates each. The 
plates were incubated overnight at 37°C and the colonies were 
counted. The numbers of colony forming units per milliliter 
(CFU/ml) were calculated after averaging of the counting results 
of the two separate plates in consideration of the dilution 
factor. Totally, 15,000 LB agar plates were plated by hand for 
66 independent experiments.
Statistical Evaluation
Statistical evaluation was performed with GraphPad PRISM 8 
(GraphPad Software, Inc., San Diego, CA, United States). Values 
of p were determined by using the independent two-sample 
t-test. We  used linear regression for calculating the minimal 
concentration for 90% bactericidal or fungicidal effects (MBC90/
MFC90), respectively, the lethal dose or concentration for 90% 
killing (LD90/LC90). All results of this study are given as MBC90/
MFC90, even though the use of LD90/LC90 is also common in 
AMP research. The use of the terms MBC/MFC may be  more 
precise from a microbiological point of view. Results with 
values of p  ≤ 0.05 were rated significant. As far as not given 
in numbers, significances are labeled as followed: *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001; and ****p ≤ 0.0001, ns = not significant.
FIGURE 1 | Western blot analyses of COLO-205 cell lysates treated with 
different batches of IL-26 dialysates, positive control, and negative control. 
Top: Detection of phospho-STAT3 using primary polyclonal rabbit-raised 
phospho-STAT3 antibodies. Bottom: Detection of STAT3α and STAT3β using 
primary polyclonal rabbit-raised STAT3 antibodies. For both analyses, 
horseradish peroxidase-conjugated anti-rabbit IgG antibodies were used as 
second reagents. Chemiluminescence detection was performed with a 
charge-coupled device camera (LAS-3000, Fujifilm, Japan).
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RESULTS
IL-26 was tested for bactericidal activities against different 
Gram-positive and Gram-negative strains of different antibiotic 
resistance phenotypes, as well as for fungicidal activities against 
C. albicans. All experiments were performed with a standardized 
protocol and were highly reproducible. The anti-infective activities 
were analyzed quantitatively for the minimal concentration for 
90% bactericidal or fungicidal effects (MBC90/MFC90).
Activity Against Enterococci
Directly after adding 50 μg/ml IL-26 to Enterococcus faecalis 
ATCC 29212 cultures, an immediate and highly significant 
(p ≤ 0.0001) reduction of the number of colony forming units 
(CFU) of approximately 98.4% was detected. After 1 h, significant 
effects were found from 5 μg/ml on. Complete eradication of 
all bacteria was reached at 50 μg/ml IL-26, after incubation 
for at least 1 h. The CFU numbers after 2, 3, and 4 h of 
incubation were reduced by 97.3, 92.3, and 96.1% at 15 μg  ml 
IL-26 (Figure  2A).
Similar to the antibiotic-sensitive type strain, a vancomycin-
resistant clinical isolate of E. faecalis showed an instant significant 
effect. After 1 h, significant CFU number reductions were found 
starting from 0.5 μg/ml, whereas the strongest results were 
observed at 15 μg/ml (reduction of 72.5%) and 50 μg/ml (99.6%). 
The reduction levels stayed constant over time. After 4 h, the 
incubation with 50 μg/ml IL-26 resulted in a highly significant 
decline of CFU numbers by 99.95% (Figure  2B).
Likewise, Enterococcus faecium ATCC 6057 showed a prompt 
significant drop of the CFU numbers at 15 μg/ml by 70.6% and 
at 50 μg/ml by 99.5%. This effect increased, when the incubation 
was performed for 1 h. Reduction values were 81.3% for 5 μg/
ml, 99.96% for 15 μg/ml, and a complete killing of all bacteria 
was achieved for 50 μg/ml. After 2 and 4 h, complete eradications 
were reached at 15 μg/ml. At 3 h, reductions amounted to 99.98% 
for 15 μg/ml and 100% for 50 μg/ml (Figure  2C).
Subsequently, we checked for IL-26 sensitivity of vancomycin-
resistant E. faecium DSM 17050 (Deutsche Sammlung von 
Mikroorganismen, German Collection of Microorganisms, 
Hannover, Germany). Again, a significant immediate decline 
by 99.1% was achieved at 50 μg/ml IL-26. After 1 h, complete 
eradication of all bacteria was reached at 50 μg/ml, whereas 
99.89% were killed at 15 μg/ml. These effects were stable 
(± 0.2% at 15 μg/ml) for 2, 3, and 4 h incubation time. After 
3 h, an additional significant but weaker effect was found at 
5 μg/ml, which lost its significance after 4 h (Figures  2D, 3).
Activity Against Staphylococcus aureus
In the case of S. aureus ATCC 6538, we  found an instant 
reduction of the CFU numbers of approximately 23.2% at 
50 μg/ml IL-26 (p = 0.37), which increased after 1 h to a highly 
significant reduction by 94.6% (p < 0.0001). Further increments 
were achieved upon ongoing incubation. CFU reductions at 
50 μg/ml reached 95.6, 98.0, and 93.4% after 2, 3, and 4 h. 
After 2 and 3 h, significant but weak effects were detectable 
at 15 μg/ml (Figure  2E).
In contrast to the antibiotic-sensitive S. aureus ATCC 
6538, the MRSA strain ATCC 33593 showed highly significant 
CFU reductions immediately after adding IL-26 to the cultures 
at 15 μg/ml with a decline by 90.1% and at 50 μg/ml by 
99.3%. These effects increased after 1 h with CFU reductions 
by 53.3% at 1.5 μg/ml, 81.4% at 5 μg/ml, 99.8% at 15 μg/ml, 
and a complete eradication of all bacteria at 50 μg/ml. After 
2 h, the effects at 5 μg/ml and 15 μg/ml were stable (±0.1%) 
and complete killing at 50 μg/ml was still achieved. When 
incubating for 3 h, reductions were found at 0.5 μg/ml (33.5%), 
1.5 μg/ml (36.5%), 5 μg/ml (83.9%), 15 μg/ml (99.8%), and 
50 μg/ml (100%), of which all were significant, besides at 
1.5 μg/ml. Last, after 4 h, declines by 63.6% at 5 μg/ml, 98.6% 
at 15 μg/ml, and complete eradication at 50 μg/ml were 
observed (Figure  2F).
Activity Against Multi-resistant  
Gram-positive Bacteria
The MBC90 for immediate effects ranged from 38.5 μg/ml (MRSA 
ATCC 33593) to 57.5 μg/ml (vancomycin-resistant E. faecalis), 
except for the methicillin-sensitive S. aureus ATCC 6538 with 
an unusually high MBC90 of 136 μg/ml. Two groups of similar 
MBC90 ranges were defined. In the first group, E. faecalis ATCC 
29212, E. faecium ATCC 6057, vancomycin-resistant 
E. faecium ATCC 17050, and MRSA ATCC 33593 had average 
MBC90 values between 12.5 μg/ml and 13.4 μg/ml IL-26 for 1 
to 3 h and 19.3 μg/ml after 4 h. In the other group, the average 
MBC90 for 1 to 4 h for vancomycin-resistant E. faecalis and 
methicillin-sensitive S. aureus ATCC 6538 ranged between 
43.7 μg/ml and 45.5 μg/ml (Table  1). Hence, we  were able to 
show for the first time that IL-26 functions as a highly active 
bactericidal agent against different Gram-positive bacteria. These 
effects are independent of the antibiotic resistance phenotypes 
since multi-resistant strains of S. aureus, E. faecalis, and 
E.  faecium were as sensitive as or even more sensitive than 
their antibiotic-sensitive counterparts.
Activity Against Acinetobacter baumannii
Concerning Gram-negative species, we first tested A. baumannii 
ATCC 19606. Similar to all tested Gram-positive bacteria, an 
initial albeit weak CFU reduction was observed. After 1 h of 
incubation, a highly significant decline of 99.8% was detected 
at 50 μg/ml IL-26 and stayed constant for 4 h (±0.3%). 
Additionally, we  found a 50% non-significant reduction at 
15 μg/ml (Figure  2G).
Moreover, two highly resistant A. baumannii CR isolates 
were analyzed, which solely were sensitive for colistin. The 
first one was isolated in 2014 from a patient from a local 
outbreak at the University Hospital Schleswig-Holstein in Kiel, 
Germany. An immediate reduction was not observed but, again, 
highly significant CFU reductions were measureable at 1, 2, 
3, and 4 h (99.4, 99.3, 99.7, and 99.7%) at IL-26 concentrations 
of 50 μg/ml (Figure  2H). The other A. baumannii CR isolate 
resulted from a patient from 2018 with previous hospitalization 
in a country with high prevalence of colonization with CR 
A. baumannii. Here, we  detected a significant immediate 
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reduction of 31.7% at 50 μg/ml IL-26. Furthermore, weaker 
and non-significant reductions were detectable at 0.5 μg/ml, 
5 μg/ml, and 15 μg/ml. After 1 h, the decline of the CFU count 
at 50 μg/ml IL-26 was 98.7% and increased in the course of 
the experiments to 99.4% (2 h), 99.8% (3 h), and 99.6% (4 h; 
Figure 2I). The mean MBC90 values for the three A. baumannii 




FIGURE 2 | Number of colony forming units per ml of different bacteria over 4 h incubation at different IL-26 concentrations. Panels (A-F) show IL-26 sensitive 
Gram-positive strains, panels (G-I) show IL-26 sensitive Gram-negative strains, and panels (J-L) show IL-26-resistant Gram-negative strains. Data are given as 
mean with standard deviation, for each strain n = 3. CFU, colony-forming units; VRE, vancomycin-resistant Enterococcus; MRSA, methicillin-resistant S. aureus; and 
CR, carbapenem resistant.
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strains (ATCC 19606, 2014, 2018) were 374.6 μg/ml for 0 h, 
46.91 μg/ml for 1 h, 48.09 μg/ml for 2 h, 46.8 μg/ml for 3 h, and 
47.22 μg/ml for 4 h (Table  1).
A. baumannii was the only tested Gram-negative 
species with IL-26 sensitivity. In contrast, we  were unable 
to detect any antimicrobial effects against E. coli ATCC 
11775, K.  pneumoniae ATCC 4352, or P. aeruginosa  
ATCC 27853 for IL-26 concentrations up to 50 μg/ml 
(Figures  2J–L).
Activity Against Candida albicans
Last, the sensitivity of C. albicans ATCC 24433 against IL-26 
was investigated. Immediate effects were not detected at up 
to 50 μg/ml IL-26. The CFU reduction values at 50 μg/ml IL-26 
were 29% after 1 h (non-significant), 67.5% after 2 h, 58.2% 
after 3 h, and 78.5% after 4 h (all significant). The MFC90 values 
ranged from 54.7 to 81.41 μg/ml (Table  1). Hence, we  were 
able to show a reproducible and significant, albeit weak fungicidal 
activity of IL-26 against C. albicans.
Thus, the cytokine IL-26 with its proinflammatory, bactericidal, 
antiviral, and fungicidal activities can be attributed to the group 
of kinocidins which was defined for cytokines with direct 
antimicrobial effects, such as human mammalian platelet factor 
4 (hPF-4; Yount et  al., 2004; Yeaman et  al., 2007; Larochette 
et  al., 2019).
DISCUSSION
Whereas all tested Gram-positive bacterial strains were highly 
sensitive to IL-26, we observed a remarkable difference between 
A. baumannii strains and all other Gram-negatives (enterobacteria 
and P. aeruginosa). Thus, the questions arise why all other 
Gram-negative species are non-sensitive for IL-26 and what 
the essential factor is for the sensitivity of A. baumannii. The 
lipopolysaccharides (LPS) and especially the O-antigen, which 
is the outer chain of the LPS, are two known factors for AMP 
resistance in Gram-negative bacteria (Silhavy et  al., 2010; Joo 
et  al., 2016). Acinetobacter species are unable to produce 
complete LPS due to the absence of O-antigen-ligase activity 
and the lipooligosaccharide (LOS) core, the lipid A, is remaining 
(Weber et  al., 2016). Thus, O-antigen might be  responsible 
for the IL-26 resistance of Gram-negative species.
Concerning the mode of IL-26 action, the direct interaction 
with the bacterial cell membrane including pore formation 
seems likely, similarly to other AMP (Patel and Akhtar, 2017). 
Due to its high cationic charge, IL-26 binds to glycosaminoglycans 
of the surface of eukaryotic cells (Hör et  al., 2004), as well 
as to LPS and lipoteichoic acid of the surface of bacteria 
(Meller et  al., 2015). Based on electron micrographs of 
P. aeruginosa ATCC 27853, bleb-formation followed by membrane 
disruption was described as the mode of IL-26 action (Meller 
et al., 2015). However, this needs to be interpreted with caution, 
since exactly the same P. aeruginosa strain has been classified 
as IL-26 resistant in this study.
The initial publication concerning antimicrobial activities of 
IL-26 described bacteriostatic effects at 50% level for 5 to 10 μM 
IL-26 against P. aeruginosa ATCC 27853, E. coli ATCC 11775, 
K. pneumoniae O1:K2, and S. aureus ATCC 6538 but no detectable 
effects against E. faecalis ATCC 29212 and C.  albicans ATCC 
24433 (Meller et  al., 2015). In contrast, our study was able to 
demonstrate strong bactericidal activities at 90% level against the 
Gram-positive strains E. faecalis ATCC 29212, vancomycin-resistant 
E. faecalis, E. faecium ATCC 6057, vancomycin-resistant E. faecium 
DSM 17050, S. aureus ATCC 6538, and MRSA ATCC 33593. 
Furthermore, we  were able to show strong effects on naturally 






FIGURE 3 | Number of colony forming units per ml (A,C,E,G,I) and 
percentage of surviving bacteria (B,D,F,H,J) for vancomycin-resistant E. 
faecium DSM 17050 for different incubation durations and different IL-26 
concentrations. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001; ns = not significant; and 
independent two-sample t-test. Mean with standard deviation, n = 3. The 
colors refer also to Figure 2.
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resistance, and weak effects on C. albicans ATCC 24433 after at 
least 2 h of incubation. Effects against E. coli ATCC 11775, 
K. pneumoniae ATCC 4352, and P. aeruginosa ATCC 27853 were 
not detectable. This goes in line with a study in which IL-26 
exhibited bacteriostatic activities against S. aureus ATCC 6538 
but not against P. aeruginosa ATCC 27853 (Scala et  al., 2019). 
Another published study did not show immediate effects for 
S.  aureus and E. coli; however, bactericidal effects were detected 
after 4 to 24 h of incubation with 1 μg/ml IL-26 (Agak et  al., 
2018). In a third publication, an activity against biofilm formation 
of S. aureus was detected which was more pronounced for IL-26 
than for the AMP LL-37 (Woetmann et  al., 2018). Regarding 
Mycobacteria (M.) IL-26 has been shown to inhibit growth and 
reduce viability of M. leprae and M. tuberculosis in axenic cultures 
as well as within macrophages, probably by inducing lysis by 
bleb-formation after interaction with lipoarabinomannan (Dang 
et  al., 2019; Hawerkamp et  al., 2020).
The reason for these functional differences might be  due 
to the different sources and qualities of commercially available 
IL-26 (Knappe et  al., 2000; Hör et  al., 2004). In order to 
ensure high quality and functionality, we  used self-produced 
IL-26 which was functionally tested for STAT3 activation in 
a colonic carcinoma cell line. Moreover, molar concentrations 
are difficult to interpret since IL-26 occurs as monomers, 
dimers, oligomers, and even multimers (Knappe et  al., 2000; 
Fickenscher et  al., 2002; Meller et  al., 2015).
Concerning the raising relevance of antibiotic-resistant bacteria, 
AMP have come under scrutiny, especially due to the lack of 
resistance development, even though they have always been present 
during evolution (Zasloff, 2002; Gallo and Hooper, 2012). Besides 
potential pharmacotechnological and galenic challenges in the 
production of this instable kinocidin, additional immunologic 
effects of the proinflammatory IL-26 need to be  considered in 
the case of a possible therapeutic application. In published 
experiments, IL-26 or LL-37 was applied nasally in mice after 
nasal application of bacteria and a certain reduction of the CFU 
number (factor 10–100) was seen (Meller et  al., 2015). However, 
these experiments were performed with K. pneumoniae, which 
was classified as IL-26 resistant in this study.
Compared to other AMP, which usually have a broad activity 
spectrum against Gram-positive and Gram-negative bacteria, 
protozoa, and fungi (Ebbensgaard et  al., 2015), IL-26 has its 
main target in Gram-positive bacteria, which has not yet been 
described for other AMP. Thus, IL-26 is a unique member of 
the family of cationic AMP. In summary, we  showed for the 
first time that IL-26 is a proinflammatory kinocidin with bactericidal 
and fungicidal activities, which is also active against A. baumannii 
and C. albicans and kills Gram-positive bacteria almost selectively.
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TABLE 1 | MBC90/MFC90 values for all IL-26-sensitive species.
Species
MBC90/MFC90
h0 1 2 3 4
E. faecalis, ATCC 29212 45.58 14.16 14.23 14.40 14.51 μg/ml
E. faecalis (VRE) 54.48 40.04 41.59 40.67 42.38 μg/ml
E. faecium, ATCC 6057 46.75 11.72 13.58 13.79 13.41 μg/ml
E. faecium (VRE), DSM 17050 42.84 12.94 14.02 12.75 13.02 μg/ml
S. aureus, ATCC 6538 136.00 47.31 46.19 47.15 48.54 μg/ml
S. aureus (MRSA), ATCC 33593 38.48 11.51 11.87 11.42 36.20 μg/ml
A. baumannii, ATCC 11775 149.40 46.12 48.42 46.21 43.36 μg/ml
A. baumannii (CR), 2014 832.10 47.15 47.90 48.18 49.97 μg/ml
A. baumannii (CR), 2018 142.30 47.46 47.96 46.02 48.32 μg/ml
C. albicans, ATCC 24433 – – 81.41 77.77 54.74 μg/ml
Data calculated by linear regression; n = 3 per species; “–”= not calculable.
Hansen et al. Bactericidal Activity of IL-26
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